List view / Grid view
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
Researchers highlight the need for a more nuanced diagnostic approach, examining whether nonglycemic markers could refine risk stratification.
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
Using phosphoproteomics, the calcium channel Cav2.3 was found as a target to treat a type of genetic epilepsy, CDKL5 deficiency disorder.
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
A new discovery about a different protective genetic mutation in apolipoprotein L1 could have major implications for kidney health.
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
With advancements in artificial intelligence, precision medicine and gene editing, the field of drug discovery is undergoing a rapid transformation. In this article, Drug Target Review’s Izzy Wood gets the insider knowledge from industry leaders at SLAS 2023, who are experiencing these changes first hand.
A novel all-optical system uses optogenetics, machine vision cameras, and off-the-shelf components to stimulate and image engineered networks of human heart cells.
A new AI model can accelerate drug discovery by accurately predicting human response to novel drug compounds.
A newly developed AAV has shown promise at delivering gene therapies to the brain in mice and non-human primates.
Join leading experts as they discuss the wide range of uses for CRISPR, including for therapeutics and biomanufacturing.
Scientists have published a report on the whole genome sequences of 150 thousand participants in the UK biobank.
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
Researchers have developed a promising new tool that accurately uses genomic data to predict disease risk across diverse populations.
